Advertisement

Topics

NICE recommends AstraZeneca lung treatment

04:51 EDT 3 Jul 2017 | Pharmafile

AstraZeneca’s Daxas (roflumilast) has received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD) is has emerged, meaning the therapy could soon be available for routine use on the NHS. The assessment covers adults whose severe COPD has not responded to other treatments.

read more

Original Article: NICE recommends AstraZeneca lung treatment

NEXT ARTICLE

More From BioPortfolio on "NICE recommends AstraZeneca lung treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all  lead to the airways in the lungs becoming damaged and thus narrower,  making inhalation and exhalation harder...